JAK2 and colonic neoplasm: In order to determine that JAK2/STAT3 signalling is indispensable for the tumour‐suppressive effect of FXR activation on colon cancer cells, colivelin and IL‐6, the agonists of JAK/STAT3 pathway,29, 30 were adopted to treat FXR‐activated cells.